Plain-English translation of NCT07439549 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new way to start buprenorphine treatment for people with opioid use disorder. The approach, called SINI (Symptom-Inhibited Naloxone Induction), uses a carefully controlled process to help your body transition onto this medication safely. The goal is to see whether this method makes starting treatment easier and more comfortable for patients.
Starting opioid addiction treatment can be challenging because beginning buprenorphine while still having opioids in your system can cause uncomfortable withdrawal symptoms. This trial is exploring whether this new approach can make the transition smoother and help more people successfully stay in treatment.
You likely qualify if…
You likely don't qualify if…
You will receive small doses of naloxone through an IV line, administered every 2 minutes until you experience mild withdrawal symptoms. Once this is achieved, you will receive a dose of buprenorphine/naloxone under the tongue. If you choose the extended-release option, you may receive an injection one hour later. After this initial induction day, you will receive ongoing treatment through a community pharmacy or clinic as part of standard care, and you will be followed for 28 days to monitor how well the treatment is working.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
Canada